Hitachi obtains FDA approval for proton beam therapy
The FDA has granted clearance for spot scanning irradiation technology of Hitachi America's Probeat proton beam therapy system to be used at the University of Texas M.D. Anderson Cancer Center in Houston.
Proton beam therapy is a localized form of radiation therapy, in which a beam of protons is focused at a tumor lying deep within the body in order to eradicate the tumor. Hitachi said it will be the first company to commercialize proton beam therapy system with spot scanning irradiation technology.
The Tarrytown, N.Y.-based Hitachi America said its Probeat proton beam therapy system employs double scatterer technology that involves two scatterers whereby the proton beam is expanded to cover the entire tumor profile.
Proton beam therapy is a localized form of radiation therapy, in which a beam of protons is focused at a tumor lying deep within the body in order to eradicate the tumor. Hitachi said it will be the first company to commercialize proton beam therapy system with spot scanning irradiation technology.
The Tarrytown, N.Y.-based Hitachi America said its Probeat proton beam therapy system employs double scatterer technology that involves two scatterers whereby the proton beam is expanded to cover the entire tumor profile.